Copertina

Editorial: When Yeast Turns Beast—Unmasking an Overlooked Threat in Alcohol‐Related Hepatitis. Authors' Reply

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Vincent Mallet, Charlotte Mouliade, Alexandre Alanio
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Editorial: When Yeast Turns Beast—Unmasking an Overlooked Threat in Alcohol‐Related Hepatitis
di: Maaz Arif, et al.
Pubblicazione: (2025)

Burden of Invasive Fungal Diseases in Patients With Alcohol‐Related Hepatitis and Organ Failure
di: Charlotte Mouliade, et al.
Pubblicazione: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Letter: Refining Mortality Estimates in Severe Alcohol–Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment. Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy—Authors' Reply
di: Tanat Saeoui, et al.
Pubblicazione: (2025)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
di: Jian Wang, et al.
Pubblicazione: (2025)

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimisation. Authors' Reply
di: Sarah Flatley
Pubblicazione: (2026)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
di: Ying‐Nan Tsai, et al.
Pubblicazione: (2025)

Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC. Authors' Reply
di: Natassia Tan, et al.
Pubblicazione: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
di: Fai Fai Ho, et al.
Pubblicazione: (2025)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply
di: Pei‐Chien Tsai, et al.
Pubblicazione: (2026)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis
di: Ewan Forrest, et al.
Pubblicazione: (2025)

Disordered Bile Acid Metabolism in Alcohol‐Related Hepatitis
di: Luke D. Tyson, et al.
Pubblicazione: (2026)

Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
di: Pinelopi Arvaniti, et al.
Pubblicazione: (2025)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations. Authors' Reply'
di: Alberto Ferrarese, et al.
Pubblicazione: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
di: Lukas Burghart, et al.
Pubblicazione: (2026)

Editorial: Food for Thought—Addressing the Nuances of Diet and Mood When Evaluating Dietary Intervention in IBS. Authors' Reply
di: Anthony O'Connor, et al.
Pubblicazione: (2024)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply
di: Ting Wang, et al.
Pubblicazione: (2024)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
di: Ramin Ebrahimi, et al.
Pubblicazione: (2025)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
di: Máté Szilcz, et al.
Pubblicazione: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
di: Jianhui Zhao, et al.
Pubblicazione: (2024)

Editorial: To Stop or Not to Stop, Is It Still a Question? Authors' Reply
di: Jeongkuk Seo, et al.
Pubblicazione: (2024)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
di: Shuaibing Ying, et al.
Pubblicazione: (2026)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar? Authors' Reply
di: Lesley A. Patmore, et al.
Pubblicazione: (2025)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
di: Luis Antonio Díaz, et al.
Pubblicazione: (2025)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis. Authors' Reply
di: Bingqiong Wang, et al.
Pubblicazione: (2025)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks—Authors' Reply
di: Rui Huang, et al.
Pubblicazione: (2025)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection—Authors' Reply
di: Yu‐Ping Chang, et al.
Pubblicazione: (2025)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky. Authors' Reply
di: Raj Vuppalanchi, et al.
Pubblicazione: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
di: Suprabhat Giri, et al.
Pubblicazione: (2025)

Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows? Authors' Reply
di: Ryan M. Mathias, et al.
Pubblicazione: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
di: Federica Tavaglione, et al.
Pubblicazione: (2025)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
di: Parul Tandon, et al.
Pubblicazione: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
di: Bharati Kochar, et al.
Pubblicazione: (2025)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
di: Jeffrey D McCurdy, et al.
Pubblicazione: (2025)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects. Authors' Reply
di: David Mehdi Asgher Niazi, et al.
Pubblicazione: (2026)

Editorial: How to Interpret Clinical Impact of Viral Replication Activity for Postoperative Recurrence of HBV‐Related HCC—Authors' Reply
di: Subin Heo, et al.
Pubblicazione: (2025)

Letter: Reassessing Tenofovir Alafenamide Use Throughout Pregnancy—A New Horizon in Hepatitis B Therapy. Authors' Reply
di: Xingfei Pan, et al.
Pubblicazione: (2025)